Cystic fibrosisNews & Research
21 curated articles for Cystic fibrosis — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society May 14, 2026
The gut microbiome: Recent findings and future opportunities in cystic fibrosis.
The gut microbiome is a key modulator of human health throughout life, from infancy to old age. Within this relatively young field, microbiome characteristics are being utilized as useful clinical endpoints and indicators of health. Moreover, microbiome-based interventions have been developed to mod...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists May 10, 2026
Aging With Cystic Fibrosis: Endocrine and Metabolic Considerations.
Cystic fibrosis (CF) has transitioned from a disease predominantly affecting the pediatric population to a chronic disease of adulthood. As patients with CF continue to prolong their survival with CF transmembrane conductance regulator modulator therapy, there has become increased relevance of age-r...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Journal of diabetes science and technology Apr 22, 2026
Use of Continuous Glucose Monitoring for Detecting and Understanding Early Dysglycemia in Cystic Fibrosis.
Cystic fibrosis-related diabetes (CFRD) is a common extrapulmonary manifestation of cystic fibrosis (CF) affecting up to 50% of adults. Cystic fibrosis-related diabetes is associated with poorer lung function, lower nutrition, and increased mortality. Abnormal blood glucoses, especially post-prandia...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Apr 21, 2026
Automated Insulin Delivery Systems in Cystic Fibrosis-Related Diabetes: A Systematic Review and Meta-Analysis.
To assess the effects of automated insulin delivery systems (AIDs) on glycemic control and selected metabolic and pulmonary outcomes in people with cystic fibrosis related diabetes (pwCFRD). We searched MEDLINE (via PubMed), Embase, and Cochrane Library for studies of AIDs in pwCFRD. Eligible studie...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- BioEssays : news and reviews in molecular, cellular and developmental biology Apr 20, 2026
Could the Phenotypic Outcomes of Genetic Variability in Cells Operating in Mechanically Dynamic Environments be Influenced by a Disrupted "Cell-ECM" Relationship? Using Cystic Fibrosis and Marfan Syndrome as an Example.
Diseases due to mutations in essential molecules can involve tissues functioning in very different environments, with some in mechanically active environments. Diseases arising from mutations in a single molecule, such as the CFTR in cystic fibrosis exhibit varied clinical phenotypes. The lung cells...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Apr 2, 2026
Gastrointestinal-related aspiration in cystic fibrosis (GRASP-CF).
The concept of gastroesophageal reflux (GER), aspiration, and swallowing dysfunction in cystic fibrosis (GRASP-CF) extends beyond GER to include esophageal dysmotility, impaired transit, and delayed gastric emptying as contributors to aspiration risk and pulmonary injury. Foregut dysfunction is comm...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- International journal of molecular sciences Mar 28, 2026
Distinct CFTR Mutation Spectrum and Atypical Clinical Presentations in Chinese Patients with Cystic Fibrosis.
Cystic fibrosis (CF) is an autosomal recessive disorder caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene and primarily affects the respiratory, digestive, and reproductive systems. Globally, CF is most prevalent among European ancestry, with an i...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Journal of clinical medicine Mar 28, 2026
Cystic Fibrosis in the Era of Precision Medicine: Transformative Progress and Persistent Challenges.
Over the past decade, the therapeutic landscape of cystic fibrosis (CF) has undergone a historic transformation; once considered a progressive, life-limiting multisystem disease treated exclusively with symptomatic therapies, CF has entered the era of mutation-specific treatment, for Contribution 1 ...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Mar 23, 2026
Cystic fibrosis year in review 2025.
Cystic fibrosis (CF) is being reshaped by CFTR modulators (CFTRm), yet infection, inflammation, and multisystem comorbidities persist. This review of the 2025 CF literature summarizes how CF is evolving into a chronic, heterogeneous condition in the modulator era. First, we discuss the consolidation...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Mar 23, 2026
CFTR correctors potentiate gating mutants causing cystic fibrosis.
The Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulator VX-445 (Elexacaftor) used to treat cystic fibrosis presents both corrector and potentiator activities. This drug binds to a pocket within the CFTR membrane-spanning domain (MSD) assembly, in contact with the lasso motif. We hav...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Obstetrics and gynecology Mar 19, 2026
Pregnancy in Patients With Cystic Fibrosis.
Cystic fibrosis (CF) is an autosomal recessive, monogenic disorder that affects individuals of all races and ethnicities. It was historically viewed as a pediatric disease, but with comprehensive care and therapeutic advances, adults with CF now outnumber children living with CF in the United States...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Hormone research in paediatrics Mar 19, 2026
Erratum.
The article "Bone Health in Young Individuals with Primary Ciliary Dyskinesia: Insights from a Comparison with Cystic Fibrosis and Healthy Controls" [Horm Res Paediatr. 2025; https://doi.org/10.1159/000549604] by Gaupmann et al. was published with the wrong open access license. The correct license o...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Expert opinion on drug delivery Mar 8, 2026
Non-viral mRNA cystic fibrosis therapies and their ongoing clinical trials.
Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to impaired ion transport by the CFTR protein and accumulation of thick, sticky mucus, resulting in chronic lung disease and other organ complications. Messen...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Nature reviews. Endocrinology Feb 15, 2026
The endocrine complications of cystic fibrosis.
Cystic fibrosis is a multisystem disorder caused by dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and is characterized by progressive pulmonary decline and exocrine pancreatic insufficiency. People with cystic fibrosis are at risk of multiple endocrine compli...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Pediatric pulmonology Feb 12, 2026
Sleep-Disordered Breathing in Cystic Fibrosis in Low- and Middle-Income Countries.
Sleep-disordered breathing (SDB) is an increasingly recognized yet underappreciated contributor to morbidity in people with cystic fibrosis (pwCF). While SDB, including nocturnal hypoxemia, hypoventilation, and obstructive sleep apnea (OSA), is well documented in high-income countries (HICs), eviden...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Paediatric respiratory reviews Feb 11, 2026
Pediatric pulmonary and sleep medicine - Best recent articles to read in 2025.
It is a challenge to select the "best" recent publications in a field. This is especially so when faced with a feast of outstanding manuscripts across a broad range of topics. I therefore reached out to a Who's Who of friends and colleagues in pediatric pulmonary and sleep medicine for suggestions, ...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Pediatric pulmonology Feb 10, 2026
Wildfire Smoke and Pediatric Lung Health: What the Clinician Needs to Know.
Wildfires are increasing over time due to climate change, resulting in increased human exposure to harmful particulate matter and other toxicants in wildfire smoke (WFS). A narrative review of literature indexed in PubMed was performed, focusing on studies of the respiratory health effects of wildfi...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Current opinion in gastroenterology Feb 5, 2026
Pathophysiology of cystic fibrosis-related liver disease.
Cystic fibrosis liver disease (CFLD) is a significant nonpulmonary complication of cystic fibrosis, affecting approximately 5-10% of patients. It encompasses a spectrum of hepatic abnormalities ranging from mild, transient elevations in liver enzymes to advanced CFLD (aCFLD), which is marked by clin...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Jan 29, 2026
Clinical effort against smoke exposure in cystic fibrosis (CEASE-CF): feasibility, acceptability, and preliminary efficacy.
Smoke exposure affects one-third of children with CF (CwCF), but smoking cessation strategies for their caregivers have not been tested. We developed and tested CEASE-CF, a randomized controlled smoking cessation intervention tailored to smoking caregivers of CwCF and delivered by a tobacco treatmen...
Why it matters: Recent peer-reviewed research on Cystic fibrosis that may be relevant for patients and caregivers.
- BreakingNEJM Nov 15, 2025
Trikafta Five-Year Data Shows Sustained Lung Function in CF
Long-term data shows sustained improvement in lung function over five years in cystic fibrosis patients with at least one F508del mutation.
Why it matters: Confirms Trikafta as transformative long-term CF therapy. 90% of CF patients now have a modulator.
- NotableCF Foundation Jul 20, 2025
CF Foundation Reaches $1B in Cumulative Research Funding
The Cystic Fibrosis Foundation announced cumulative research funding exceeding $1 billion.
Why it matters: Model for how patient advocacy can directly fund and accelerate drug development.
More on Cystic fibrosis
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.